Page last updated: 2024-09-02

ramosetron and Adenoma, Basal Cell

ramosetron has been researched along with Adenoma, Basal Cell in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ando, T; Ikeoka, T; Imaizumi, M; Kawakami, A; Ueki, I; Usa, T	1

Other Studies

1 other study(ies) available for ramosetron and Adenoma, Basal Cell

Article	Year
Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron. Endocrine, 2014, Volume: 46, Issue:1 Topics: Adenoma; Adult; Aged; Antiemetics; Benzimidazoles; Domperidone; Dose-Response Relationship, Radiation; Female; Fluid Therapy; Humans; Iodine Radioisotopes; Male; Middle Aged; Nausea; Risk Factors; Thyroid Neoplasms; Vomiting	2014

Article

Year

Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.

Endocrine, 2014, Volume: 46, Issue:1

Topics: Adenoma; Adult; Aged; Antiemetics; Benzimidazoles; Domperidone; Dose-Response Relationship, Radiation; Female; Fluid Therapy; Humans; Iodine Radioisotopes; Male; Middle Aged; Nausea; Risk Factors; Thyroid Neoplasms; Vomiting

2014